MYRIAD GENETICS INC — Director's Dealing 2021

Aug 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2021-08-05

Reporting Person: Phanstiel S. Louise (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-05	Common Stock	M	30000	$25.39	Acquired	109527	Direct
2021-08-05	Common Stock	S	47881	$35.0398	Disposed	61646	Direct
2021-08-05	Common Stock	M	30000	$21.29	Acquired	91646	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-05	Non-Qualified Stock Option (right to buy)	$21.29	M	30000	Disposed	2021-12-02	Common Stock (30000)	Direct
2021-08-05	Non-Qualified Stock Option (right to buy)	$25.39	M	30000	Disposed	2021-12-05	Common Stock (30000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21000	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.49 to $35.50, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares subject to this option are fully vested and exercisable.